1-20 of 35
Hans Gelderblom
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety, Efficacy and Biomarker Analysis of Crizotinib in MET Mutated Non-Small Cell Lung Cancer – Results from the Drug Rediscovery Protocol

Karlijn Verkerk, Tijmen J.W.T. van der Wel, Laurien J. Zeverijn, Birgit S. Geurts, Ilse A.C. Spiekman, Gijs F. de Wit, Paul Roepman, Anne M.L. Jansen, Vincent van der Noort, Egbert F. Smit, Ann Hoeben, Lizza E.L. Hendriks, Michel M. Van den Heuvel, Berber Piet, Gerarda J.M. Herder, Sayed M.S. Hashemi, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest, Adrianus J. de Langen
Journal: Clinical Cancer Research
Clin Cancer Res (2024)
https://doi.org/10.1158/1078-0432.CCR-24-1925
Published: 01 October 2024
View article titled, Safety, Efficacy and Biomarker Analysis of Crizotinib in MET Mutated Non-Small Cell Lung Cancer – Results from the Drug Rediscovery Protocol
Open the PDF for Safety, Efficacy and Biomarker Analysis of Crizotinib in MET Mutated Non-Small Cell Lung Cancer – Results from the Drug Rediscovery Protocol in another window
Includes: Supplementary data
Journal Articles

The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol

Laurien J. Zeverijn, Birgit S. Geurts, Thomas W. Battaglia, Jade M. van Berge Henegouwen, Gijs F. de Wit, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Paul Roepman, Wendy W.J. de Leng, Anne M.L. Jansen, Myriam Chalabi, Carla M.L. van Herpen, Lot A. Devriese, Frans L.G. Erdkamp, Mariette Labots, Maja J.A. de Jonge, Emile D. Kerver, Adriaan D. Bins, Lindsay V.M. Leek, Jessica C.L. Notohardjo, Alfonsus J.M. van den Eertwegh, Lodewyk F.A. Wessels, Henk M.W. Verheul, Hans Gelderblom, Joris van de Haar, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (19): 4339–4351.
https://doi.org/10.1158/1078-0432.CCR-24-0480
Published: 01 October 2024
View article titled, The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
Open the PDF for The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol in another window
Includes: Supplementary data
Journal Articles

CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib

Hans Gelderblom, Albiruni A. Razak, Matthew H. Taylor, Todd M. Bauer, Breelyn Wilky, Javier Martin-Broto, Alejandro F. Gonzalez, Piotr Rutkowski, Bartlomiej Szostakowski, Thierry Alcindor, Ramy Saleh, Sofia Genta, Silvia Stacchiotti, Michiel van de Sande, Andrew J. Wagner, Nicholas Bernthal, Lara E. Davis, Jacqueline Vuky, Christopher Tait, Bahar Matin, Supraja Narasimhan, Maitreyi G. Sharma, Rodrigo Ruiz-Soto, Matthew L. Sherman, William D. Tap
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 3996–4004.
https://doi.org/10.1158/1078-0432.CCR-24-0103
Published: 13 September 2024
View article titled, CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib
Open the PDF for CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib in another window
Includes: Supplementary data
Journal Articles

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol

Birgit S. Geurts, Laurien J. Zeverijn, Lindsay V.M. Leek, Jade M. van Berge Henegouwen, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Joris van de Haar, Annemiek van Ommen-Nijhof, Marleen Kok, Paul Roepman, Anne M.L. Jansen, Wendy W.J. de Leng, Maja J.A. de Jonge, Ann Hoeben, Carla M.L. van Herpen, Hans M. Westgeest, Lodewyk F.A. Wessels, Henk M.W. Verheul, Hans Gelderblom, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3735–3746.
https://doi.org/10.1158/1078-0432.CCR-24-0011
Published: 03 September 2024
View article titled, Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Open the PDF for Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol in another window
Includes: Supplementary data
Journal Articles

Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol

Jade M. van Berge Henegouwen, Laurien J. Zeverijn, Birgit S. Geurts, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Alwin D.R. Huitema, Filip Y.F. de Vos, Katrien Grünberg, Haiko J. Bloemendal, Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3937–3943.
https://doi.org/10.1158/1078-0432.CCR-23-3917
Published: 03 September 2024
View article titled, Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
Open the PDF for Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol in another window
Includes: Supplementary data
Journal Articles

Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement

Darrell Green, Roelof van Ewijk, Elisa Tirtei, Dimosthenis Andreou, Fredrik Baecklund, Daniel Baumhoer, Stefan S. Bielack, Rajesh Botchu, Kjetil Boye, Bernadette Brennan, Michael Capra, Lucia Cottone, Uta Dirksen, Franca Fagioli, Natalia Fernandez, Adrienne M. Flanagan, Marco Gambarotti, Nathalie Gaspar, Hans Gelderblom, Craig Gerrand, Anne Gomez-Mascard, Jendrik Hardes, Stefanie Hecker-Nolting, Edita Kabickova, Leo Kager, Jukka Kanerva, Lennart A. Kester, Marieke L. Kuijjer, Valérie Laurence, Cyril Lervat, Antonin Marchais, Perrine Marec-Berard, Cristina Mendes, Johannes H.M. Merks, Benjamin Ory, Emanuela Palmerini, Pan Pantziarka, Evgenia Papakonstantinou, Sophie Piperno-Neumann, Anna Raciborska, Elizabeth A. Roundhill, Vilma Rutkauskaite, Akmal Safwat, Katia Scotlandi, Eric L. Staals, Sandra J. Strauss, Didier Surdez, Gwen M.L. Sys, Marie-Dominique Tabone, Maud Toulmonde, Claudia Valverde, Michiel A.J. van de Sande, Klaus Wörtler, Quentin Campbell-Hewson, Martin G. McCabe, Michaela Nathrath
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (16): 3395–3406.
https://doi.org/10.1158/1078-0432.CCR-24-0101
Published: 15 August 2024
View article titled, Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement
Open the PDF for Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement in another window
Journal Articles

Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial

Raphael Koch, Lianne Haveman, Ruth Ladenstein, Benedicte Brichard, Heribert Jürgens, Sona Cyprova, Henk van den Berg, Wolf Hassenpflug, Anna Raciborska, Torben Ek, Daniel Baumhoer, Gerlinde Egerer, Leo Kager, Marleen Renard, Peter Hauser, Stefan Burdach, Judith V.M.G. Bovee, Angela M. Hong, Peter Reichardt, Jarmila Kruseova, Arne Streitbürger, Thomas Kühne, Torsten Kessler, Marie Bernkopf, Trude Butterfaß-Bahloul, Catharina Dhooge, Sebastian Bauer, János Kiss, Michael Paulussen, Fiona Bonar, Andreas Ranft, Beate Timmermann, Jelena Rascon, Volker Vieth, Jukka Kanerva, Andreas Faldum, Wolfgang Hartmann, Lars Hjorth, Vivek A. Bhadri, Markus Metzler, Hans Gelderblom, Uta Dirksen
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (24): 5057–5068.
https://doi.org/10.1158/1078-0432.CCR-23-1966
Published: 15 December 2023
View article titled, Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
Open the PDF for Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial in another window
Includes: Supplementary data
Journal Articles

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study

Bruno Vincenzi, Andrea Napolitano, Marta Fiocco, Olivier Mir, Piotr Rutkowski, Jean-Yves Blay, Peter Reichardt, Heikki Joensuu, Elena Fumagalli, Spyridon Gennatas, Nadia Hindi, Margherita Nannini, Mariella Spalato Ceruso, Antoine Italiano, Giovanni Grignani, Antonella Brunello, Silvia Gasperoni, Tommaso De Pas, Giuseppe Badalamenti, Maria A. Pantaleo, Winan J. van Houdt, Nikki S. IJzerman, Neeltje Steeghs, Hans Gelderblom, Ingrid M.E. Desar, Johanna Falkenhorst, Marianna Silletta, Marta Sbaraglia, Giuseppe Tonini, Javier Martin-Broto, Peter Hohenberger, Axel Le Cesne, Robin L. Jones, Angelo P. Dei Tos, Alessandro Gronchi, Sebastian Bauer, Paolo G. Casali
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1672–1679.
https://doi.org/10.1158/1078-0432.CCR-21-1665
Published: 14 April 2022
View article titled, Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
Open the PDF for Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study in another window
Includes: Supplementary data
Journal Articles

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Louisa R. Hoes, Jade M. van Berge Henegouwen, Hanneke van der Wijngaart, Laurien J. Zeverijn, Daphne L. van der Velden, Joris van de Haar, Paul Roepman, Wendy J. de Leng, Anne M.L. Jansen, Erik van Werkhoven, Vincent van der Noort, Alwin D.R. Huitema, Eelke H. Gort, Jan Willem B. de Groot, Emile D. Kerver, Derk Jan de Groot, Frans Erdkamp, Laurens V. Beerepoot, Mathijs P. Hendriks, Egbert F. Smit, Winette T.A. van der Graaf, Carla M.L. van Herpen, Mariette Labots, Ann Hoeben, Hans Morreau, Martijn P. Lolkema, Edwin Cuppen, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1402–1411.
https://doi.org/10.1158/1078-0432.CCR-21-3752
Published: 01 April 2022
View article titled, Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Open the PDF for Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment in another window
Includes: Supplementary data
Journal Articles

Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib

Che-Jui Lee, Patrick Schöffski, Elodie Modave, Tom van Wezel, Bram Boeckx, Jozef Sufliarsky, Hans Gelderblom, Jean-Yves Blay, Maria Debiec-Rychter, Raf Sciot, Judith V.M.G. Bovée, Diether Lambrechts, Agnieszka Wozniak
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6737–6748.
https://doi.org/10.1158/1078-0432.CCR-21-1165
Published: 15 December 2021
View article titled, Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib
Open the PDF for Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib in another window
Includes: Supplementary data
Journal Articles

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study

Sebastian Bauer, Michael C. Heinrich, Suzanne George, John R. Zalcberg, César Serrano, Hans Gelderblom, Robin L. Jones, Steven Attia, Gina D'Amato, Ping Chi, Peter Reichardt, Julie Meade, Ying Su, Rodrigo Ruiz-Soto, Jean-Yves Blay, Margaret von Mehren, Patrick Schöffski
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6333–6342.
https://doi.org/10.1158/1078-0432.CCR-21-1864
Published: 01 December 2021
View article titled, Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <em>KIT/PDGFRA</em> Mutations in the Phase III INVICTUS Study
Open the PDF for Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <em>KIT/PDGFRA</em> Mutations in the Phase III INVICTUS Study in another window
Includes: Supplementary data
Journal Articles

Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types

Hanneke van der Wijngaart, Louisa R. Hoes, J. Maxime van Berge Henegouwen, Daphne L. van der Velden, Laurien J. Zeverijn, Paul Roepman, Erik van Werkhoven, Wendy W.J. de Leng, Anne M.L. Jansen, Niven Mehra, Debbie G.J. Robbrecht, Mariette Labots, Derk Jan A. de Groot, Ann Hoeben, Paul Hamberg, Hans Gelderblom, Emile E. Voest, Henk M.W. Verheul
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (22): 6106–6114.
https://doi.org/10.1158/1078-0432.CCR-21-1104
Published: 15 November 2021
View article titled, Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types
Open the PDF for Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types in another window
Includes: Supplementary data
Journal Articles

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bedard, Chia-Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine A. Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (13): 3620–3629.
https://doi.org/10.1158/1078-0432.CCR-20-4746
Published: 01 July 2021
View article titled, Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
Open the PDF for Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials

Olivier Mir, Nathan Touati, Michela Lia, Saskia Litière, Axel Le Cesne, Stefan Sleijfer, Jean-Yves Blay, Michael Leahy, Robin Young, Ron H.J. Mathijssen, Nielka P. Van Erp, Hans Gelderblom, Winette T. Van der Graaf, Alessandro Gronchi
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (5): 1479–1485.
https://doi.org/10.1158/1078-0432.CCR-18-2748
Published: 01 March 2019
View article titled, Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials
Open the PDF for Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials in another window
Includes: Supplementary data
Journal Articles

Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies

Lawrence L'Italien, Olivia Orozco, Tinya Abrams, Lisa Cantagallo, Anu Connor, Jayesh Desai, Hilmar Ebersbach, Hans Gelderblom, Keith Hoffmaster, Emma Lees, Heiko Maacke, Siew Schleyer, Darko Skegro, Si Tuen Lee-Hoeflich
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (14): 3465–3474.
https://doi.org/10.1158/1078-0432.CCR-17-3786
Published: 15 July 2018
View article titled, Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies
Open the PDF for Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies in another window
Includes: Supplementary data
Journal Articles

Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma

David G.P. van IJzendoorn, Stefan Sleijfer, Hans Gelderblom, Ferry A.L.M. Eskens, Geert J.L.H. van Leenders, Karoly Szuhai, Judith V.M.G. Bovée
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (11): 2678–2687.
https://doi.org/10.1158/1078-0432.CCR-17-3512
Published: 31 May 2018
View article titled, Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma
Open the PDF for Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma in another window
Includes: Supplementary data
Journal Articles

A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma

Xiaoyan Liu, Jesse J. Swen, Meta H.M. Diekstra, Epie Boven, Daniel Castellano, Hans Gelderblom, Ron H.J. Mathijssen, Sita H. Vermeulen, Egbert Oosterwijk, Kerstin Junker, Max Roessler, Kristin Alexiusdottir, Asgerdur Sverrisdottir, Marius T. Radu, Valentin Ambert, Tim Eisen, Anne Warren, Cristina Rodríguez-Antona, Jesus García-Donas, Stefan Böhringer, Karel K.M. Koudijs, Lambertus A.L.M. Kiemeney, Brian I. Rini, Henk-Jan Guchelaar
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (10): 2350–2356.
https://doi.org/10.1158/1078-0432.CCR-17-2815
Published: 14 May 2018
View article titled, A Genetic Polymorphism in <em>CTLA-4</em> Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma
Open the PDF for A Genetic Polymorphism in <em>CTLA-4</em> Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment

Melanie M. Hagleitner, Marieke J.H. Coenen, Hans Gelderblom, Remco R. Makkinje, Hanneke I. Vos, Eveline S.J.M. de Bont, Winette T.A. van der Graaf, H.W. Bart Schreuder, Uta Flucke, Frank N. van Leeuwen, Peter M. Hoogerbrugge, Henk-Jan Guchelaar, Dunja M.W.M te Loo
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (15): 3436–3441.
https://doi.org/10.1158/1078-0432.CCR-14-2638
Published: 02 August 2015
View article titled, A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment
Open the PDF for A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment in another window
Includes: Supplementary data
Journal Articles

Radium-223 Chloride: Extending Life in Prostate Cancer Patients by Treating Bone Metastases

Michel D. Wissing, Fijs W.B. van Leeuwen, Gabri van der Pluijm, Hans Gelderblom
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (21): 5822–5827.
https://doi.org/10.1158/1078-0432.CCR-13-1896
Published: 31 October 2013
View article titled, Radium-223 Chloride: Extending Life in Prostate Cancer Patients by Treating Bone Metastases
Open the PDF for Radium-223 Chloride: Extending Life in Prostate Cancer Patients by Treating Bone Metastases in another window
Journal Articles

Tales of How Great Drugs Were Brought Down by a Flawed Rationale—Letter

Michel D. Wissing, Michael A. Carducci, Hans Gelderblom, Paul J. van Diest
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (5): 1303.
https://doi.org/10.1158/1078-0432.CCR-12-2695
Published: 03 March 2013
View article titled, Tales of How Great Drugs Were Brought Down by a Flawed Rationale—Letter
Open the PDF for Tales of How Great Drugs Were Brought Down by a Flawed Rationale—Letter in another window